ROBERT H LURIE CANCER CENTER BREAST CANCER PROGRAM

全国对乳腺癌的关注要求将重点放在 翻译研究将迅速将新的实验室创新引入 诊所。总体目标是提高乳腺癌的治疗水平 并开发预防乳腺癌的新策略。要做到这一点 目标需要了解基本的实验室策略和 与乳腺癌相关的临床问题。西北大学医学院 学校通过建立新的乳房来回应国家的关注 中间。目前这项提议的目的是发展一种乳腺癌 计划与特定的研究实验室和一个集中的基本团队 科学家和临床医生通过罗伯特·H·卢里癌症中心。这个 研究团队将与多学科的乳房建立联系 癌症治疗团队。罗伯特·H·卢里癌症中心是一家NCI- 指定的癌症中心整合了该中心的专业知识和资源 医学院部门及其五家附属医院以及 位于埃文斯顿校区的基础科学系。这个 机构在乳腺癌相关的基础和 临床研究。目标是在现有的基础上建立一个新的计划 一支才华横溢的调查团队。将支持四个试点项目 此提案的第一年。项目1涉及研究基因治疗 乳腺癌的活体治疗 使用乳腺细胞特异性启动子给药治疗载体。 项目2涉及生产突变的雌激素受体以阻断正常 受体介导的信号通路。项目3评估内分泌 乳腺癌患者接受他莫昔芬治疗的情况。项目4是为了 开发检测乳汁中生长因子的方法，以确定 乳腺癌潜在的中间生物学标志物。最新的 该方案招募的主任是V.Craig Jordan，Ph.D.，D.Sc，a 科学家和乳腺癌外科医生莫妮卡·莫罗医学博士。这个团队是 因他们在乳腺癌方面的开创性工作而闻名国际 为发展一流的乳腺癌项目提供独特的机会 在卢里癌症中心。

The national concern about breast cancer has mandated a focus on translational research to introduce new laboratory innovations rapidly into the clinic. The overall goal is to improve the treatment of breast cancer and to develop new strategies in breast cancer prevention. To achieve this goal requires an understanding of both basic laboratory strategies and clinical issues relevant to breast cancer. Northwestern University Medical School has responded to the national concern by establishing a new breast center. The aim of the current proposal is to develop a breast cancer program with specific research laboratories and a centralized team of basic scientists and clinicians through the Robert H. Lurie Cancer Center. The research team will have established links with the multidisciplinary breast cancer treatment team. The Robert H. Lurie Cancer Center is an NCI- designated cancer center integrating the expertise and resources of the Medical School departments with its five affiliated hospitals along with those of basic science departments located on the Evanston campus. The institution has significant strengths in breast cancer-related basic and clinical research. The goal is to establish a new program from the existing team of talented investigators. Four pilot projects will be supported for year 1 of this proposal. Project #1 involves studying gene therapy for treatment of breast cancer using in vivo administration of therapeutic vectors using breast cell-specific promoters. Project #2 involves production of mutant estrogen receptors to block normal receptor mediated signalling pathways. Project #3 assesses the endocrine status of breast cancer patients receiving tamoxifen. Project #4 is to develop assays to measure growth factors in breast fluid to identify potential intermediate biological markers for breast cancer. The newly recruited directors of the Program are V. Craig Jordan, Ph.D., D.Sc., a scientist, and a breast cancer surgeon, Monica Morrow, M.D.. The team is internationally known for their pioneering work in breast cancer and will provide a unique opportunity to develop a first class breast cancer program at the Lurie Cancer Center.